Retroviral gene transfer of tissue-type plasminogen activator targets thrombolysis in vitro and in vivo.
Patients usually have serious complications of thrombosis and bleeding by eating anticoagulation medicine for their residual lives after mechanical valve replacement operation. Tissue-type plasminogen activator (tPA) could target thrombolysis by activating plasminogen to fibrinolysin. In this study, we recombined a retroviral vector pLEGFP-N1-tPA and cultured purified packaging cells PT67/pLEGFP-N1-tPA to produce high-titer retrovirus. In vitro, two target cells, endothelial cell of umbilical vein (ECUV) 304 and heart muscle cell (HMC) that consist of endocardium and heart muscle, were infected by pLEGFP-N1-tPA. The results demonstrated that exogenous tPA was successfully transferred into ECUV304 and HMC. tPA in the two cells shows significant thrombolysis in plasma plate and the activity and content of tPA were high. Furthermore, in vivo, no thrombus was seen on the surface of Dacron patches (the same material making up a ring of mechanical valve) by tPA locally transferring around Dacron patches that were transplanted in the inferior caval veins of rabbits. tPA was successfully transferred into the local inferior caval vein. Activity and content of tPA were high in local tissue and blood and thrombolysis was effectively demonstrated by tPA rapidly, efficiently and long expressing. This laid the foundation for study and appliance of the tPA gene valve.
Gong
Y S
YS
1Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhang
K L
KL
Jiang
X G
XG
Wang
Z W
ZW
Sun
Z Q
ZQ
Cai
J
J
D000818:Animals; D002460:Cell Line; D002478:Cells, Cultured; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D006801:Humans; D008854:Microscopy, Electron; D023421:Models, Animal; D011093:Polyethylene Terephthalates; D019736:Prostheses and Implants; D011817:Rabbits; D012190:Retroviridae / Q000235:genetics*; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000378:metabolism / Q000628:therapy*; D010959:Tissue Plasminogen Activator / Q000235:genetics* / Q000378:metabolism; D014682:Vena Cava, Inferior / Q000378:metabolism
D011093:Polyethylene Terephthalates; D010959:Tissue Plasminogen Activator